US FDA Panel For Sarepta’s Gene Therapy Heavy On Temporary Voting Members

 
• By Sue Sutter

Only four of 14 voting panelists are regular members of the Cellular, Tissues and Gene Therapies Advisory Committee, with scheduling conflicts precluding participation by many others, the FDA said. Three of the temporary members are veterans of prior muscular dystrophy drug reviews.

Telephone
In setting the panel for the Sarepta gene therapy meeting, the US FDA has called on experts from prior muscular dystrophy drug reviews. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers